Therapy and Prophylaxis of Peritoneal Metastases from Colorectal Cancer

Czech version

Authors: Libor Nemec ¹; Jiří Tomášek ^2,3; Roman Šefr ^1,3
Authors‘ workplace: Klinika operační onkologie, Masarykův onkologický ústav, Brno ¹; Klinika komplexní onkologické péče, Masarykův onkologický ústav, Brno 3 LF MU, Brno ²
Published in: Klin Onkol 2019; 32(5): 338-344
Category: Review
doi: https://doi.org/10.14735/amko2019338

Overview

Stage IV colorectal cancer is associated with high mortality, and the prognosis is significantly worse for patients have peritoneal metastases. Peritoneal carcinomatosis from colorectal cancer was considered incurable with an infaust prognosis. Median survival of untreated patients is about 6 months and palliative systemic chemotherapy can prolonge this time up to 20 months. Patients with this disease were previously only surgically treated if they had severe clinical symptoms or complications. This view has changed dramatically over the past 15 years. Aggressive cytoreductive surgery in combination with intraperitoneal chemotherapy may prolong median survival for more than 40 months in selected patients. The Peritoneal Surface Oncology Group International (PSOGI), the international authority on the treatment of peritoneal tumors, recommends cytoreduction with intraperitoneal chemotherapy as the standard of care for selected patients with moderate-to-small volume peritoneal metastases secondary to colorectal cancer. Macroscopic cytoreduction appears to be essential; however, the role of hyperthermic intraperitoneal chemotherapy and the optimal chemotherapeutic agent for intraperitoneal lavage to treat peritoneal metastases from colorectal cancer remain unclear. The results of ongoing and future clinical trials are eagerly awaited.

Keywords:

cytoreductive surgery – hyperthermic intraperitoneal chemotherapy – peritoneal carcinomatosis – colorectal cancer

Sources

1. Zavoral M, Vojtěchová G, Suchánek Š. Klasifikace kolorektálního karcinomu. Onkologie 2013; 7 (4): 172–175.

2. Krška Z, Hoskovec D, Petruželka L et al. Chirurgická onkologie. Praha: Grada Publishing 2014.

3. Simkens GA, Rovers KP, Nienhuijs SW et al. Patient selection for cytoreductive surgery and HIPEC for the treatment of peritoneal metastases from colorectal cancer. Cancer Manag Res 2017; 9: 259–266. doi: 10.2147/CMAR.S119569.

4. Elias D, Honoré C, Dumont F et al. Results of systematic second-look surgery plus HIPEC in asymptomatic patients presenting a high risk of developing colorectal peritoneal carcinomatosis. Ann Surg 2011; 254 (2): 289–293. doi: 10.1097/SLA.0b013e31822638f6.

5. Rosen SA, Buell JF, Yohida A et al. Initial presentation with stage IV colorectal cancer. Arch Surg 2000; 135 (5): 503–505. doi: 10.1001/archsurg.135.5.530.

6. Simkens GA, Razenberg LG, Lemmens VE et al. Histological subtype and systemic metastases strongly influence treatment and survival in patients with synchronous colorectal peritoneal metastases. Eur J Surg Oncol 2016; 42 (6): 794–800. doi: 10.1016/j.ejso.2016.03.014.

7. Hess KR, Varadhachary GR, Taylor SH et al. Metastatic patterns in adenocarcinoma. Cancer 2006; 106 (7): 1624–1633. doi: 10.1002/cncr.21778.

8. Lemmens VE, Klaver YL, Verwaal VJ et al. Predictors and survival of synchronous peritoneal carcinomatosis of colorectal origin: a population-based study. Int J Cancer 2011; 128 (11): 2717–2725. doi: 10.1002/ijc.25596.

9. Segelman J, Granath F, Holm T et al. Incidence, prevalence and risk factors for peritoneal carcinomatosis from colorectal cancer. Br J Surg 2012; 99 (5): 699–705. doi: 10.1002/bjs.8679.

10. Kerscher AG, Chua TC, Gasser M et al. Impact of peritoneal carcinomatosis in the disease history of colorectal cancer management: a longitudinal experience of 2406 patients over two decades. Br J Cancer 2013; 108 (7): 1432–1439. doi: 10.1038/bjc.2013.82.

11. Segelman J, Akre O, Gustafsson UO et al. A. Individualized prediction of risk of metachronous peritoneal carcinomatosis from colorectal cancer. Colorectal Dis 2014; 16 (5): 359–367. doi: 10.1111/codi.12552.

12. Koppe MJ, Boerman OC, Oyen WJ et al. Peritoneal carcinomatosis of colorectal origin: incidence and current treatment strategies. Ann Surg 2006; 243 (2): 212–222. doi: 10.1097/01.sla.0000197702.46394.16.

13. Kok NFM, de Hingh IHJT. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal metastases of colorectal origin. BJS 2017; 104 (4): 313–315. doi: 10.1002/bjs.10422.

14. Franko J, Shi Q, Meyers JP et al. Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database. Lancet Oncol 2016; 17 (12): 1709–1719. doi: 10.1016/S1470-2045 (16) 30500-9.

15. Razenberg LG, van Gestel YR, Creemers GJ et al. Trends in cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for the treatment of synchronous peritoneal carcinomatosis of colorectal origin in the Netherlands. Eur J Surg Oncol 2015; 41 (4): 466–471. doi: 10.1016/j.ejso.2015.01.018.

16. Bhatt A (ed). Management of peritoneal metastases-cytoreductive surgery, HIPEC and beyond. Singapore: Springer 2018.

17. Verwaal VC, van Ruth S, de Bree E et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis from colorectal cancer. J Clin Oncol 2003; 21 (20): 3737–3743. doi: 10.1200/JCO.2003.04.187.

18. Elias D, Delperro JR, Sideris L et al. Treatment of peritoneal carcinomatosis from colorectal cancer: impact of complete cytoreductive surgery and difficulties in conducting randomized trials. Ann Surg Oncol 2004; 11 (5): 518–521. doi: 10.1245/ASO.2004.09.008.

19. Elias D, Lefevre JH, Chevalier J et al. Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin. J Clin Oncol 2009; 27 (5): 681–685. doi: 10.1200/JCO.2008.19.7160.

20. Elias D, Gilly F, Boutitie F et al. Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study. J Clin Oncol 2010; 28 (1): 63–68. doi: 10.1200/JCO.2009.23.9285.

21. Esquivel J, Lowy AM, Markman M et al. The American Society of Peritoneal Surface Malignancies (ASPSM) multi-institution evaluation of the Peritoneal Surface Disease Severity Score (PSDSS) in 1,013 patients with colorectal cancer with peritoneal carcinomatosis. Ann Surg Oncol 2014; 21 (13): 4195–4201. doi: 10.1245/s10434-014-3798-z.

22. Glehen O, Kwiatkowski F, Sugarbaker PH et al. Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study. J Clin Oncol 2004; 22 (16): 3284–3292. doi: 10.1200/JCO.2004.10.012.

23. Kuijpers AM, Mirck B, Aalbers AG et al. Cytoreduction and HIPEC in the Netherlands: nationwide long-term outcome following the Dutch protocol. Ann Surg Oncol 2013; 20 (13): 4224–4230. doi: 10.1245/s10434-013-3145-9.

24. Goere D, Malka D, Tzanis D et al. Is there a possibility of a cure in patients with colorectal peritoneal carcinomatosis amenable to complete cytoreductive surgery and intraperitoneal chemotherapy? Ann Surg 2013; 257 (6): 1065–1071. doi: 10.1097/SLA.0b013e31827e9289.

25. Vassos N, Förtsch T, Aladashvili A et al. Repeated cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with recurrent peritoneal carcinomatosis. World J Surg Oncol 2016; 14 (1): 42. doi: 10.1186/s12957-016-0804-x.

26. Esquivel J, Piso P, Verwaal V et al. American Society of Peritoneal Surface Malignancies opinion statement on defining expectations from cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with colorectal cancer. J Surg Oncol 2014; 110 (7): 777–778. doi: 10.1002/jso.23722.

27. Chua TC, Esquivel J, Pelz JO et al. Summary of current therapeutic options for peritoneal metastases from colorectal cancer. J Surg Oncol 2013; 107 (6): 566–573. doi: 10.1002/jso.23189.

28. El-Nakeep S, Rashad N, Oweira H et al. Intraperitoneal chemotherapy and cytoreductive surgery for peritoneal metastases coupled with curative treatment of colorectal liver metastases: an updated systematic review. Expert Rev Gastroenterol Hepatol 2017; 11 (3): 249–258. doi: 10.1080/17474124.2017.1284586.

29. Kwakman R, Schrama AM, van Olmen JP et al. Clinicopathological parameters in patient selection for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal cancer metastases: a meta-analysis. Ann Surg 2016; 263 (6): 1102–1111. doi: 10.1097/SLA.0000000000001593.

30. Elias D, Faron M, Goéré D et al. A simple tumor load-based nomogram for surgery in patients with colorectal liver and peritoneal metastases. Ann Surg Oncol 2014; 21 (6): 2052–2058. doi: 10.1245/s10434-014-3506-z.

31. Quenet F, Elias D, Roca L et al. A UNICANCER phase III trial of hyperthermic intra-peritoneal chemotherapy (HIPEC) for colorectal peritoneal carcinomatosis (PC): PRODIGE 7. J Clin Oncol 2018; 36 (Suppl): abstr. LBA3 503.

32. März L, Piso P. Treatment of peritoneal metastases from colorectal cancer. Gastroenterol Rep 2015; 3 (4): 298–302. doi: 10.1093/gastro/gov044.

33. Goere D, Souadka A, Faron M et al. Extent of colorectal peritoneal carcinomatosis: attempt to define a threshold above which HIPEC does not offer survival benefit: a comparative study. Ann Surg Oncol 2015; 22 (9): 2958–2964. doi: 10.1245/s10434-015-4387-5.

34. Elias D, Mariani A, Cloutier AS et al. Modified selection criteria for complete cytoreductive surgery plus HIPEC based on peritoneal cancer index and small bowel involvement for peritoneal carcinomatosis of colorectal origin. Eur J Surg Oncol 2014; 40 (11): 1467–1473. doi: 10.1016/j.ejso.2014.06.006.

35. Esquivel J, Piso P, Verwaal V et al. American Society of Peritoneal Surface Malignancies opinion statement on defining expectations from cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with colorectal cancer. J Surg Oncol 2014; 110 (7): 777–778. doi: 10.1002/jso.23722.

36. Sugarbaker PH. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of gastrointestinal cancers with peritoneal metastases: progress toward a new standard of care. Cancer Treat Rev 2016; 48: 42–49. doi: 10.1016/j.ctrv.2016.06.007.

37. Baratti D, Kusamura S et al. Progress in treatments for colorectal cancer peritoneal metastases during the years 2010–2015. A systematic review. Crit Rev Oncol Hematol 2016; 100: 209–222. doi: 10.1016/j.critrevonc.2016.01.017.

38. Pelz JO, Stojadinovic A, Nissan A et al. Evaluation of a peritoneal surface disease severity score in patients with colon cancer with peritoneal carcinomatosis. J Surg Oncol 2009; 99 (1): 9–15. doi: 10.1002/jso.21169.

39. Simkens GA, van Oudheusden TR, Nieboer D et al. Development of a prognostic nomogram for patients with peritoneally metastasized colorectal cancer treated with cytoreductive surgery and HIPEC. Ann Surg Oncol 2016; 23 (13): 4214–4221. doi: 10.1245/s10434-016-5211-6.

40. Cashin PH, Graf W, Nygren P et al. Patient selection for cytoreductive surgery in colorectal peritoneal carcinomatosis using serum tumor markers: an observational cohort study. Ann Surg 2012; 256 (6): 1078–1083. doi: 10.1097/SLA.0b013e318254f281.

41. Enblad M, Ghanipour L, Cashin PH. Prognostic scores for colorectal cancer with peritoneal metastases treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Int J Hyperthermia 2018; 34 (8): 1390–1395. doi: 10.1080/02656736.2018.1464668.

42. Kozman MA, Fisher OM, Rebolledo BJ et al. CEA to peritoneal carcinomatosis index (PCI) ratio is prognostic in patients with colorectal cancer peritoneal carcinomatosis undergoing cytoreduction surgery and intraperitoneal chemotherapy: a retrospective cohort study. J Surg Oncol 2018; 117 (4): 725–736. doi: 10.1002/jso.24911.

43. Sugarbaker PH, Glehen O. Management of unexpected peritoneal metastases with primary colorectal cancer using second-look surgery with HIPEC. Can Surg 2015; 1: 101.

44. Arjona-Sánchez A, Medina-Fernández FJ, Muñoz-Casares FC et al. Peritoneal metastases of colorectal origin treated by cytoreduction and HIPEC: an overview. World J Gastrointest Oncol 2014; 6 (10): 407–412. doi: 10.4251/wjgo.v6.i10.407.

45. Sugarbaker PH. Second-look surgery for colorectal cancer: revised selection factors and new treatment options for greater success. Int J Surg Oncology 2011; 2011: 915078. doi: 10.1155/2011/915078.

46. Cortes-Guiral D, Elias D, Cascales-Campos PA et al. Second-look surgery plus hyperthermic intraperitoneal chemotherapy for patients with colorectal cancer at high risk of peritoneal carcinomatosis: Does it really save lives? World J Gastroenterol 2017; 23 (3): 377–381. doi: 10.3748/wjg.v23.i3.377.

47. Verwaal VJ. Long-term results of cytoreduction and HIPEC followed by systemic chemotherapy. Cancer J 2009; 15 (3): 212–215. doi: 10.1097/PPO.0b013e3181a58d7c.

48. Sugarbaker PH, van der Speeten K. Surgical technology and pharmacology of hyperthermic perioperative chemotherapy. Gastrointest Oncol 2016; 7 (1): 29–44. doi: 10.3978/j.issn.2078-6891.2015.105.

49. Klaver CEL et al. Adjuvant hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with colon cancer at high risk of peritoneal carcinomatosis; the COLOPEC randomized multicentre trial. BMC Cancer 2015; 15: 428. doi: 10.1186/s12885-015-1430-7.

50. Goere D, Glehen O, Quenet F et al. Results of a randomized phase 3 study evaluating the potential benefit of a second-look surgery plus HIPEC in patients at high risk of developing colorectal peritoneal metastases (PROPHYLOCHIP-NTC01226394). J Clin Oncol 2018; 36 (Suppl): abstr. 3531.

51. Arjona-Sánchez A, Barrios P, Boldo-Roda E et al. HIPECT4: multicentre, randomized clinical trial to evaluate safety and efficacy of Hyperthermic intra-peritoneal chemotherapy (HIPEC) with Mitomycin C used during surgery for treatment of locally advanced colorectal carcinoma. BMC Cancer 2018; 18 (1): 183. doi: 10.1186/s12885-018-4096-0.